RT Journal Article
SR Electronic
T1 Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20228692
DO 10.1101/2020.11.11.20228692
A1 Huang, Q. Sue
A1 Wood, Tim
A1 Jelley, Lauren
A1 Jennings, Tineke
A1 Jefferies, Sarah
A1 Daniells, Karen
A1 Nesdale, Annette
A1 Dowell, Tony
A1 Turner, Nikki
A1 Campbell-Stokes, Priscilla
A1 Balm, Michelle
A1 Dobinson, Hazel C
A1 Grant, Cameron C.
A1 James, Shelley
A1 Aminisani, Nayyereh
A1 Ralston, Jacqui
A1 Gunn, Wendy
A1 Bocacao, Judy
A1 Danielewicz, Jessica
A1 Moncrieff, Tessa
A1 McNeill, Andrea
A1 Lopez, Liza
A1 Waite, Ben
A1 Kiedrzynski, Tomasz
A1 Schrader, Hannah
A1 Gray, Rebekah
A1 Cook, Kayla
A1 Currin, Danielle
A1 Engelbrecht, Chaune
A1 Tapurau, Whitney
A1 Emmerton, Leigh
A1 Martin, Maxine
A1 Baker, Michael G.
A1 Taylor, Susan
A1 Trenholme, Adrian
A1 Wong, Conroy
A1 Lawrence, Shirley
A1 McArthur, Colin
A1 Stanley, Alicia
A1 Roberts, Sally
A1 Ranama, Fahimeh
A1 Bennett, Jenny
A1 Mansell, Chris
A1 Dilcher, Meik
A1 Werno, Anja
A1 Grant, Jennifer
A1 van der Linden, Antje
A1 Youngblood, Ben
A1 Thomas, Paul G.
A1 Webby, Richard J.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.11.20228692.abstract
AB Stringent nonpharmaceutical interventions (NPIs) such as lockdowns and border closures are not currently recommended for pandemic influenza control. New Zealand used these NPIs to eliminate coronavirus disease 2019 during its first wave. Using multiple surveillance systems, we observed a parallel and unprecedented reduction of influenza and other respiratory viral infections in 2020. This finding supports the use of these NPIs for controlling pandemic influenza and other severe respiratory viral threats.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe SHIVERS-II project is funded by US National Institute of Allergy and Infectious Diseases (NIAID) (CEIRS Contract HHSN272201400006C). The WellKiwis (i.e. SHIVERS-III) project is funded by US-NIAID (U01 AI 144616). The SARI and ILI surveillance were funded by the NZ Ministry of Health during 2017-2020 and by US-Centers for Disease Control and Prevention (U01IP000480) during 2012-2016. The funding resource has no role in study design; collection, analysis or interpretation of data; writing of reports; nor decision to submit papers for publicationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained for the SHIVERS (including SARI and ILI surveillance), SHIVERS-II and III cohort studies from the NZ Northern A Health and Disability Ethics Committee (NTX/11/11/102). The ICD-coded influenza hospitalisation data and laboratory-based respiratory virus surveillance data are part of public health surveillance in NZ. It is conducted in accordance with the Public Health Act and thus ethics committee approval was not needed for collection or use of these data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request